Product Information
FETZIMA ER 40 MG CAPSULE is a brand product labeled by Allergan, Inc., priced at $17.6112 per EA under NDC 00456224030. Its NADAC has been published 655 times since Mar 19, 2014.
FDA first approved this application on Jul 25, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Allergan, Inc.NDC
00456224030
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOMILNACIPRAN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA204168FDA Approved
7/25/2013
TE Code
AB
On Market Since
7/25/2013
Pharmacological Classes
Price Statistics
The NADAC for FETZIMA ER 40 MG CAPSULE has been published 655 times since Mar 19, 2014, and over the history we have for it it has risen 166.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.6112 per EA |
|---|---|
| All-time high | $17.6363 (Aug 12, 2026) |
| All-time low | $6.5408 (Apr 23, 2014) |
| 52-week high | $17.6363 |
| 52-week low | $16.7909 |
| Median price | $13.1146 |
| Average price | $12.7851 |
| Largest weekly change | +16.9% (Oct 8, 2014) |
| Weeks tracked | 655 |
| Tracking since | Mar 19, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LEVOMILNACIPRAN HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LEVOMILNACIPRAN HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FETZIMA ER 40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FETZIMA ER 40 MG CAPSULE, manufactured by Allergan, Inc., is $17.6112 per EA (NDC 00456224030), effective Sep 30, 2026.
How has the price of FETZIMA ER 40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FETZIMA ER 40 MG CAPSULE has risen 166.4%. It has been tracked across 655 weekly CMS publications since Mar 19, 2014.
What are the highest and lowest recorded NADAC prices for FETZIMA ER 40 MG CAPSULE?
Since Mar 19, 2014, the NADAC for FETZIMA ER 40 MG CAPSULE has ranged from a low of $6.5408 (Apr 23, 2014) to a high of $17.6363 (Aug 12, 2026), with a median of $13.1146 per EA.
Are there cheaper alternatives to FETZIMA ER 40 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of FETZIMA ER 40 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FETZIMA ER 40 MG CAPSULE?
FETZIMA ER 40 MG CAPSULE (NDC 00456224030) is labeled by Allergan, Inc., and CMS classifies it as a brand product.